Human embryonic stem cells are pluripotent stem cells derived from the inner cell mass of a blastocyst, an early-stage pre-implantation embryo. These cells are capable of dividing without differentiation and have the potential to develop into any cell type in the body, including neurons, heart, pancreatic, and liver cells. Due to this ability of self-renewal and differentiation, human embryonic stem cells hold immense potential in cell therapy and disease modeling applications.

The global human embryonic stem cells market is estimated to be valued at US$ 1258.02 Mn in 2023 and is expected to exhibit a CAGR of 12% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:

The opportunity in cell therapy and disease modeling is expected to drive the growth of the human embryonic stem cells market during the forecast period. Human embryonic stem cells are being used in transplant medicine for treating various neurodegenerative diseases such as Parkinson's disease and spinal cord injuries. In addition, researchers are developing stem cell-based disease models to better understand disease development and progression using human embryonic stem cells. This is increasing the adoption of embryonic stem cells in drug discovery and development processes. Therefore, increasing research activities in these applications are expected to boost the demand for human embryonic stem cells over the coming years.

Porter's Analysis

Threat of new entrants: The Global Human Embryonic Stem Cells Market Size requires high R&D investments and strict regulatory approvals which act as a barrier for new companies. However, the growing market opportunities attract new startups.

Bargaining power of buyers: The presence of many research institutes and pharmaceutical companies gives buyers a bargaining power in this market. Buyers can negotiate on price and demand value-added services.

Bargaining power of suppliers: Due to the specialized nature of supply and limited number of capability providers, suppliers have a strong bargaining power. They can influence pricing and have control over supply.

Threat of new substitutes: No close substitutes exist for embryonic stem cells currently. Alternatives like adult or induced pluripotent stem cells do not match efficacy but gain popularity.

Competitive rivalry: The market sees competition between research organizations and companies. Firms compete on research collaborations, new discoveries, and technological advancements.

SWOT Analysis

Strength: Wide application scope in regenerative medicine and drug discovery. Embryonic stem cells can differentiate into any cell type.
Weakness: Ethical issues related to human embryo destruction. Risk of immune rejection post transplantation.
Opportunity: Growing stem cell banking facilities and emerging cell therapy market. Increasing collaborations and tech developments.
Threats: Stringent regulations delay commercialization. COVID-19 impacts reduced investment in non-COVID research.

Key Takeaways

The global human embryonic stem cells market is expected to witness high growth over the forecast period.

Regional Analysis: North America dominates currently owing to presence of major research institutes and advanced healthcare system. The United States and Canada contribute significantly to regional market growth.

Key players operating in the human embryonic stem cells market are Estee Lauder, L'Oreal, Shiseido, P&G, Unilever, LVMH, Chanel, Amorepacific, LG Household and Healthcare, Kanabo, Tatcha, Drunk Elephant, Olay, La Mer, Kiehl's, Clarins, Origins, Caudalie, Dr. Barbara Sturm, SkinCeuticals. Major players focus on collaborations, new product launches, and clinical research to strengthen their market position.

Get More Insights On This Topic: https://www.newswirestats.com/human-embryonic-stem-cells-market-forecast-outlook-trend-2023-2030/